future glp-1 drugs Market Size to Hit USD 132.79 Bn by 2035 Market Overview: GLP-1 Agonists and

planned completion May 2019), and dulaglutide (REsearching Cardiovascular Events with a Weekly INcretin in Diabetes [REWIND

In addition, regulatory bodies are adapting to the evolving landscape, which may facilitate faster approvals for innovative therapies

Recommendations emphasized risk stratification of individual patients and weighing the risks vs the benefits of holding or continuing GLP-1 and GLP-1/GIP combination receptor agonist medications

nausea and vomiting were, however, higher for lixisenatide-treated patients

It does this by increasing insulin secretion and reducing the amount of glucose produced by the liver

While insulin is used to regulate blood sugar directly, Ozempic also aids in weight loss by reducing appetite and promoting satiety